The aim of this study is to establish the risk and frequency of non-symptomatic hypoglycemia
in type 2 diabetes under previous therapy with glibenclamide. Participants will be monitored
via a continuous glucose monitoring system in a standardized clinical setting during day and
night time, implementing meals and exercise of moderate intensity performed in the
postprandial state.